Person:
Nieto Martinez, Francisco Javier

Profile Picture
First Name
Francisco Javier
Last Name
Nieto Martinez
Institution
ISCIII
Centrre
ISCIII::Centro Nacional de Microbiología (CNM)
CNIC Organization
CNIO Organization
Institute
Identifiers
ORCIDScopus Author ID

Filters

2006 - 20073
Reset filters

Settings

End date: 2009 × Start date: 2006 ×

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Publication
    Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis
    (Elsevier, 2007-07-20) Moreno, Javier; Nieto Martinez, Francisco Javier; Masina, S; Cañavate, Carmen; Cruz, Israel; Chicharro, Carmen; Carrillo, Eugenia; Napp, S; Reymond, C; Kaye, P M; Smith, D F; Fasel, N; Alvar, Jorge; RMF Dictagene; Novartis; Fonds de la Recherche Scientifique (Belgique)
    The protective capabilities of three Leishmania recombinant proteins - histone 1 (H1) and hydrophilic acylated surface protein B1 (HASPB1) immunized singly, or together as a protein cocktail vaccine with Montanide, and the polyprotein MML immunized with MPL-SE adjuvant - were assessed in beagle dogs. Clinical examination of the dogs was carried out periodically under blinded conditions and the condition of the dogs defined as asymptomatic or symptomatic. At the end of the trial, we were able to confirm that following infection with L. infantum promastigotes, five out of eight dogs immunized with H1 Montanide, and four out of eight dogs immunized with either the combination of HASPB1 with Montanide or the combination of H1+HASPB1 with Montanidetrade mark, remained free of clinical signs, compared with two out of seven dogs immunized with the polyprotein MML and adjuvant MPL-SE, and two out of eight dogs in the control group. The results demonstrate that HASPB1 and H1 antigens in combination with Montanide were able to induce partial protection against canine leishmaniasis, even under extreme experimental challenge conditions.
  • Thumbnail Image
    Publication
    Leishmania/HIV co-infections in the second decade.
    (Medknow Publications, 2006-03) Cruz, Israel; Nieto Martinez, Francisco Javier; Moreno, Javier; Cañavate, Carmen; Desjeux, Philippe; Alvar, Jorge
    Leishmania-HIV co-infection has been globally controlled in Southern Europe since 1997 because of highly active anti retroviral therapy (HAART), but it appears to be an increasing problem in other countries such as Ethopia, Sudan, Brazil or India where both infections are becoming more and more prevalent. Most of the scientific background on Leishmania/HIV co-infection has been dropped from the Mediterranean experience and although the situations among countries are not fully comparable, it is of high importance to take advantage of this knowledge. In this review several aspects of the Leishmania/HIV co-infection are emphasized viz., epidemiological features, new ways of transmission, pathogenesis, clinical outcome, diagnosis, treatment and secondary prohylaxis. An extensive review of the literature on Leishmania/HIV co-infection has allowed the inclusion of a comprehensive and updated list of bibliographical references.
  • No Thumbnail Available
    Publication
    Comparison of new diagnostic tools for management of pediatric Mediterranean visceral leishmaniasis
    (American Society for Microbiology (ASM), 2006-07) Cruz, Israel; Chicharro, Carmen; Nieto Martinez, Francisco Javier; Bailo-Barroso, Begoña; Cañavate, Carmen; Figueras, María-Concepción; Alvar, Jorge; Gilead Sciences (Spain); World Health Organization (WHO/OMS); RETICS-Investigación colaborativa en Enfermedades Tropicales (RICET-ISCIII) (España); Instituto de Salud Carlos III
    New techniques are available for diagnosing leishmaniasis, but their efficacy in the identification of pediatric visceral leishmaniasis (VL) has not been compared with that of traditional methods. Blood, bone marrow, and urine samples were taken from 25 children with VL during their first clinical episode, 22 days after the start of treatment with liposomal amphotericin B (3 mg/kg/day on 6 days over a 10-day period), and when a relapse was suspected during follow-up. The results obtained suggest that antibody detection techniques, the antigen detection in urine (KAtex kit), and Leishmania nested PCR (LnPCR) analysis of the blood could be used for diagnosis of the first clinical episode. After treatment, clinical improvement was associated with negativization of Novy-MacNeal-Nicolle culture and microscopy of bone marrow aspirate, KAtex test, and LnPCR blood analysis results. Interestingly, LnPCR analysis of the bone marrow aspirate showed that sterile cure was not achieved in eight patients, two of which suffered a relapse within 10 to 20 weeks. All of the new noninvasive techniques tested showed high diagnostic sensitivity. However, LnPCR analysis of the bone marrow was the most sensitive; this test was able to detect the persistence of parasites and predict potential relapses.